Impact of probiotic supplementation on mortality of induced 1,2-dimethylhydrazine carcinogenesis in a mouse model.
ABSTRACT Probiotic bacterial strains have been increasingly used in clinical practice as many health benefits result from their use. However, severe side effects such as bacteremia and fungemia have been reported in inmunocompromised patients and those with chronic disease.
The purpose of this study was to report the impact of probiotic supplementation on the mortality of mice undergoing carcinogenesis induction with 1,2-dimethylhydrazine (DMH).
Two treatment protocols were used. In experiment 1, Lactobacillus delbrueckii UFV-H2b20, Bifidobacterium animalis var. lactis Bb12, and Saccharomyces boulardii were added to the drinking water, to control mice and those undergoing injections of DMH daily. Probiotic supplementation was started 1 wk before and continued throughout the 6 wk of DMH injections. In experiment 2, the same probiotics were administered daily, except on the first day that DMH was administered. The mortality of these animals was recorded. Bacterial translocation was determined in mice in experiment 1.
Groups with DMH-induced injury treated with lactobacilli, bifidobacteria, and the mixture of lactobacilli and bifidobacteria presented with 40%, 30%, and 60% mortality, respectively. Death happened mainly between 48 h and 72 h after the first injection of DMH. On the other hand, no mice in experiment 2 died during the study period. Bacteria were found to be translocated to mesenteric lymph nodes, spleen, and liver.
Supplementation of L. delbrueckii UFV-H2b20 and B. animalis var. lactis Bb12 in mice with DMH-induced injury led to death in some animals. The results suggest that increased bacterial translocation was probably related to mortality. These findings are an alert to the potentially severe side effects associated with the use of probiotics under extremely stressful situations.
- SourceAvailable from: ncbi.nlm.nih.gov[show abstract] [hide abstract]
ABSTRACT: We report an outbreak of Saccharomyces cerevisiae subtype boulardii fungemia among three intensive care unit roommates of patients receiving lyophilized preparations of this fungus. The fungemia was probably due to central venous catheter contamination and resolved after fluconazole treatment. The need for stringent application of proper hygiene when using a probiotic preparation of this organism is emphasized.Journal of Clinical Microbiology 12/2003; 41(11):5340-3. · 4.07 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Saccharomyces boulardii (Sb) is a particular strain of Saccharomyces cerevisiae (Sc). This viable yeast is used in intensive care adult patients, delivered in packets of 500 mg, for preventing diarrhea associated with antibiotics or enteral feeding at a regimen of 1-2 g/day. Between June 1996 and October 1998, seven cases of fungemia with Sb occurred in a 12-bed intensive care unit (ICU). All the patients concerned were severely ill patients, mechanically ventilated, treated by broad spectrum antibiotics with central venous catheter and were pretreated with Sb, except for one patient. In this study, Sb was identified by specific mycologic methods and confirmed the genomic identity between isolates of blood culture and yeasts from the treatment packets, contrary to a few other reports concerning Saccharomyces species published in international literature. The hypothesis discussed for explaining these cases of Sb fungemia are: (1) an intestinal translocation of Sb administered at a high dosage in severely ill patients, (2) a contamination of the central venous catheter, especially in the patient not pretreated with Sb and (3) a massive colonization of critically ill patients by the yeast as has been reported for Candida species. We note that cases of fungemia with Sc and Sb have become more and more frequent in the international literature during the last 10 years and we do not recommend administering Sb treatment in critically ill patients.Intensive Care Medicine 07/2002; 28(6):797-801. · 5.26 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Pseudomonas . Food antioxidants such as glutathione, vitamin E, and β-carotenes are important. Ingredients for the colonic mucosa are important. Approximately 10% of caloric need is satisfied by so-called colonic food (prebiotics), fermented at the level of the colonic mucosa to produce colonic mucosa nutrients and to prevent gut origin sepsis. More than 10 g of fiber per day is recommended. The fermenting flora (probiotic flora) is deranged owing to disease or antibiotic treatment, and resupply of flora is important. A new concept of ecoimmune nutrition is presented for enteral supply of mucosa-reconditioning ingredients: new surfactants, pseudomucus, fiber, amino acids such as arginine, and mucosa-adhering Lactobacillus plantarum 299.World Journal of Surgery 01/1996; 20(4):474-481. · 2.23 Impact Factor